Opinion
Video
Arvin K. George, MD, provides update on the PRESERVE trial
Author(s):
Key Takeaways
- The PRESERVE trial evaluates Irreversible Electroporation for prostate tissue ablation, seeking a specific indication for prostate cancer treatment.
- Irreversible Electroporation is already FDA-approved for soft tissue ablation, but the trial aims to expand its clinical application.
The PRESERVE trial is evaluating the safety and effectiveness of Irreversible electroporation for prostate tissue ablation.
In this video, Arvin K. George, MD, touches on the status of the PRESERVE trial (NCT04972097), which is evaluating the safety and effectiveness of Irreversible electroporation for prostate tissue ablation. George is an associate professor of clinical urology and director of the prostate cancer programs at Johns Hopkins Medicine in Baltimore, Maryland.
Video Transcript:
It's interesting that you asked that question, because stay tuned; these results are imminent. At the current time we're waiting for the FDA. Then, based on that, we'll be able to release the results. That will be, hopefully, even potentially, as a late-breaking abstract at the AUA. Irreversible electroporation is already being used commercially, because it does have FDA approval for soft tissue ablation. The current trial, which is the PRESERVE trial, is looking at prostate tissue ablation, which would give it essentially a more specific indication that I think will expand our ability to use it in our patients.
This transcript was AI generated and edited by human editors for clarity.
